Active Ingredient
Ceftriaxone Sodium equivalent to Ceftriaxone 250mg per vial for intramuscular injection
What Oxidil IM Injection 250mg Is Used For
Oxidil IM Injection 250mg contains ceftriaxone, a third-generation cephalosporin antibiotic administered by intramuscular injection for the treatment of moderate to severe bacterial infections in adults and children. This medication is indicated for:
- Lower respiratory tract infections including community-acquired pneumonia, bronchopneumonia, and acute exacerbations of chronic obstructive pulmonary disease caused by susceptible bacterial organisms
- Skin and soft tissue infections including cellulitis, wound infections, and infected skin ulcers requiring parenteral antibiotic therapy
- Urinary tract infections including complicated urinary tract infections and pyelonephritis where oral therapy is insufficient or not feasible
- Acute bacterial otitis media in children and adults where the infection has not responded to first-line oral antibiotics or where parenteral therapy is clinically indicated
- Uncomplicated gonorrhea caused by susceptible strains of Neisseria gonorrhoeae
- Pelvic inflammatory disease as part of a combination treatment regimen
- Intra-abdominal infections including peritonitis in combination with appropriate anaerobic coverage
- Surgical prophylaxis before certain procedures to prevent postoperative infections
Ceftriaxone belongs to the third-generation cephalosporin class of beta-lactam antibiotics and works by inhibiting bacterial cell wall synthesis. Specifically, ceftriaxone binds to and irreversibly inactivates penicillin-binding proteins located on the inner membrane of bacterial cell walls. This disrupts the final stages of peptidoglycan cross-linking, an essential structural component of the bacterial cell wall, causing the wall to weaken and rupture, ultimately resulting in bacterial cell death. Ceftriaxone demonstrates broad-spectrum activity against a wide range of gram-positive and gram-negative bacteria and is notable for its exceptionally long half-life of approximately 6-8 hours, which allows once or twice daily dosing and is a key clinical advantage over earlier generation cephalosporins requiring more frequent administration.
Important Safety Information
Who Should NOT Receive Oxidil IM Injection 250mg
Do not administer this medication to patients who have a known hypersensitivity or anaphylactic reaction to ceftriaxone, any other cephalosporin antibiotic, or any excipients in the formulation, have a history of severe immediate hypersensitivity reaction to penicillin antibiotics, as there is a clinically significant cross-reactivity risk between penicillins and cephalosporins, are neonates aged 41 weeks or younger corrected gestational age, are hyperbilirubinemic neonates or premature neonates as ceftriaxone can displace bilirubin from albumin binding sites causing dangerous bilirubin encephalopathy, or require calcium-containing intravenous solutions simultaneously as the combination can cause potentially fatal ceftriaxone-calcium precipitation in the lungs and kidneys, particularly in neonates.
Serious Warnings and Precautions
Hypersensitivity and Anaphylaxis: Serious and potentially fatal hypersensitivity reactions including anaphylaxis, anaphylactic shock, angioedema, and severe cutaneous reactions can occur with ceftriaxone administration, even in patients with no prior history of cephalosporin allergy. The risk is higher in patients with a known history of penicillin allergy due to cross-reactivity between beta-lactam antibiotic classes. Before administering Oxidil IM Injection, a thorough allergy history must be obtained from the patient or caregiver. Emergency treatment facilities including epinephrine, antihistamines, corticosteroids, airway management equipment, and resuscitation capabilities must be immediately available during and following administration. Patients should remain under observation for at least 30 minutes after injection for early detection of hypersensitivity reactions.
Ceftriaxone-Calcium Precipitation: Ceftriaxone must never be mixed with or administered simultaneously through the same intravenous line as calcium-containing solutions or calcium-containing products including Ringer's solution, Hartmann's solution, and parenteral nutrition containing calcium. The combination forms insoluble ceftriaxone-calcium salt precipitates that can deposit in the lungs and kidneys, causing potentially fatal pulmonary and renal complications. This interaction is of greatest clinical significance and most severe consequence in neonates, for whom concurrent use of ceftriaxone and any calcium-containing intravenous preparation is absolutely contraindicated regardless of the route or timing of administration.
Clostridium difficile-Associated Diarrhea: Antibiotic use, including ceftriaxone, significantly disrupts the normal gastrointestinal flora and is associated with an increased risk of Clostridium difficile infection, ranging in severity from mild diarrhea to life-threatening pseudomembranous colitis. This risk persists for weeks to months after completing antibiotic treatment. If a patient develops persistent watery or bloody diarrhea, abdominal cramping, or fever during or after treatment with ceftriaxone, Clostridium difficile infection must be considered and investigated promptly. Do not use antidiarrheal medications that reduce intestinal motility in patients suspected of having Clostridium difficile colitis, as this can worsen the condition.
Biliary Complications: Ceftriaxone can precipitate in bile, causing biliary sludge, pseudolithiasis (formation of calcium-ceftriaxone precipitates in the gallbladder that can mimic gallstones), and rarely symptomatic cholelithiasis. This is more common with higher doses, longer treatment duration, and in patients with pre-existing biliary tract abnormalities. Biliary symptoms including right upper quadrant pain, nausea, and vomiting occurring during ceftriaxone therapy should be investigated with ultrasound. These precipitates typically resolve after discontinuation of the medication.
Hemolytic Anemia: Immune-mediated hemolytic anemia, in some cases severe and life-threatening, has been reported with ceftriaxone use. If a patient develops signs of anemia including pallor, unusual fatigue, rapid heartbeat, or shortness of breath, or if laboratory tests reveal a significant decrease in hemoglobin during treatment, ceftriaxone should be stopped immediately and hemolytic anemia investigated.
Superinfection and Antimicrobial Resistance: Prolonged use of ceftriaxone, as with all broad-spectrum antibiotics, can suppress susceptible organisms and allow overgrowth of resistant bacteria and fungi, leading to superinfection. If signs of a new infection develop during treatment, appropriate cultures should be obtained and alternative antimicrobial coverage considered. Ceftriaxone should only be used for confirmed or strongly suspected bacterial infections and should not be used for viral infections such as the common cold or flu.
Seizure Risk: Although uncommon at standard doses, seizures have been reported in patients receiving ceftriaxone, particularly those with renal impairment or those receiving high doses. Use with caution in patients with a history of seizure disorders and monitor neurological status in high-risk patients.
Notify the attending medical team or seek emergency assistance immediately if the patient develops signs of anaphylaxis during or following injection including urticaria, bronchospasm, facial swelling, hypotension, or cardiovascular collapse, experiences signs of severe hemolytic anemia, develops signs of Clostridium difficile infection including severe diarrhea, abdominal pain, or systemic illness, experiences biliary pain or jaundice during treatment, develops signs of superinfection including new fever, worsening symptoms, or evidence of new infection, or shows signs of unexpected neurological changes including seizures.
Consult Your Doctor Before Use If You Have:
A history of allergy to any cephalosporin or penicillin antibiotic, renal impairment of any severity, hepatic impairment, a history of gastrointestinal disease particularly colitis, biliary tract disease or gallbladder problems, a history of seizure disorders or epilepsy, are pregnant or breastfeeding, are a neonate or premature infant where use requires extreme caution and specialist oversight, have pre-existing hemolytic anemia or blood disorders, are receiving concurrent medications that may interact with ceftriaxone, are malnourished or have vitamin K deficiency as cephalosporins can affect prothrombin time, or take warfarin or other anticoagulants as ceftriaxone can enhance their anticoagulant effect.
Common Side Effects
Oxidil IM Injection is generally well-tolerated when administered correctly. However, patients may experience pain, discomfort, and local reactions at the intramuscular injection site, diarrhea or loose stools, nausea, vomiting, abdominal discomfort, headache, elevated liver enzymes on blood tests, elevated blood urea or creatinine, rash or skin reactions, and eosinophilia detected on blood count. Injection site pain can be reduced by reconstituting the powder with 1% lidocaine solution rather than water for injection, where this is clinically appropriate and where the patient has no history of lidocaine allergy.
Serious adverse effects requiring immediate medical intervention include anaphylaxis and severe hypersensitivity reactions, severe cutaneous reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis, immune hemolytic anemia, Clostridium difficile pseudomembranous colitis, ceftriaxone-calcium precipitation in lungs or kidneys, symptomatic biliary complications, seizures, and significant hematological changes including thrombocytopenia, neutropenia, and prolonged prothrombin time.
Drug Interactions
Inform the prescribing doctor or administering healthcare professional about all medications the patient is currently taking. Clinically significant interactions include those with warfarin and other anticoagulants where ceftriaxone can enhance anticoagulant effects and increase bleeding risk requiring more frequent INR monitoring during and after treatment, calcium-containing intravenous solutions and preparations where concurrent use is absolutely contraindicated due to the risk of fatal precipitation, aminoglycoside antibiotics such as gentamicin and amikacin where the combination carries increased nephrotoxicity risk requiring renal function monitoring and the two medications must never be mixed in the same solution, probenecid which reduces renal elimination of certain cephalosporins although the interaction is less pronounced with ceftriaxone due to its primarily biliary excretion, oral contraceptives where broad-spectrum antibiotic use may theoretically reduce contraceptive effectiveness and patients should be counseled accordingly, live bacterial vaccines including typhoid vaccine where antibiotic use may reduce vaccine effectiveness and concurrent administration should be avoided, loop diuretics including furosemide where concurrent use may increase nephrotoxicity risk particularly in patients with pre-existing renal impairment, and any other nephrotoxic medications where concurrent administration requires careful monitoring of renal function.
How Oxidil IM Injection 250mg Is Administered
Oxidil IM Injection must only be prepared and administered by or under the direct supervision of a trained healthcare professional. It is formulated specifically for intramuscular administration and must not be administered intravenously in this formulation without appropriate reconstitution and verification of suitability for intravenous use.
Reconstitution: Reconstitute the 250mg vial with the appropriate volume of compatible diluent as specified in the manufacturer's instructions. For intramuscular injection, reconstitution with 1% lidocaine hydrochloride solution is commonly used to reduce injection site pain, provided the patient has no history of hypersensitivity to local anesthetic agents and lidocaine is clinically appropriate. Never reconstitute with calcium-containing solutions. Inspect the reconstituted solution visually for particulate matter and discoloration before administration. Use only clear solutions without visible particles.
Standard Adult Dosing: For most infections, the recommended adult dose is 1-2g once daily or in equally divided doses twice daily depending on the type and severity of infection. For uncomplicated gonorrhea, a single intramuscular dose of 250mg or 500mg is typically administered. For surgical prophylaxis, a single dose is administered 30-90 minutes before the procedure. Specific dosing for each indication must be determined by the prescribing physician based on current clinical guidelines, local antimicrobial resistance patterns, infection severity, and patient-specific factors.
Pediatric Dosing: Dosing in children is calculated based on body weight, typically 50-75mg per kilogram per day for most infections, not exceeding adult doses. Dosing for meningitis and other serious infections may differ. Pediatric dosing must always be verified by the prescribing physician or clinical pharmacist and must never exceed the recommended maximum daily dose for the indication being treated.
Administration Technique: Inject deep into a large muscle mass, typically the gluteal muscle or lateral thigh in children, using correct intramuscular injection technique to minimize pain and reduce the risk of inadvertent intravascular injection. Do not inject into the same site repeatedly. Volumes greater than 2ml per injection site should be divided between two sites. Apply gentle pressure to the injection site after administration without massaging, which can increase drug leakage and local reaction.
Duration of Treatment: The duration of ceftriaxone therapy depends on the type and severity of infection, the clinical response, and microbiological results. Most infections require 5-14 days of treatment. For gonorrhea, a single dose is typically sufficient. The treating physician must determine the appropriate duration based on clinical response and microbiological findings. Antibiotic therapy should not be discontinued prematurely upon symptomatic improvement, as this risks incomplete eradication of the infection and development of antibiotic resistance.
Based on our pharmacists' clinical observations, the most common practical challenges with intramuscular ceftriaxone administration include injection site pain, which can be significantly reduced by reconstitution with lidocaine solution, ensuring the injection is administered deep into an adequate muscle mass, and using the correct gauge and length of needle for the patient's body habitus. Patients receiving ceftriaxone for community-acquired infections should be clearly counseled on the importance of completing the full prescribed course of antibiotic therapy even when symptoms improve, the importance of returning for subsequent injections on schedule, the signs of allergic reaction to report immediately, and the significance of diarrhea that develops during or after antibiotic treatment.
What Healthcare Providers and Patients Need to Know
Antibiotic Stewardship: Ceftriaxone is a broad-spectrum third-generation cephalosporin and its clinical use should be guided by antibiotic stewardship principles. It should be prescribed for confirmed or strongly suspected bacterial infections where the likely causative organisms fall within its spectrum of activity. Empirical use should be based on local resistance patterns and clinical guidelines. Where possible, culture and sensitivity testing should guide definitive therapy and allow de-escalation to a narrower-spectrum antibiotic once susceptibility results are available. Indiscriminate use of broad-spectrum cephalosporins contributes to the global emergence of antibiotic-resistant organisms including extended-spectrum beta-lactamase-producing bacteria.
Culture Before Treatment: Wherever clinically feasible, appropriate specimens for culture and sensitivity testing should be collected before initiating ceftriaxone therapy. This ensures that the infecting organism's susceptibility to ceftriaxone is confirmed and allows rational de-escalation or modification of therapy based on laboratory results. Early empirical treatment should not be delayed in seriously ill patients while awaiting culture results, but specimen collection must precede antibiotic administration where possible.
Penicillin Allergy Cross-Reactivity: The true rate of cross-reactivity between penicillins and cephalosporins is lower than historically estimated, with current evidence suggesting a rate of approximately 1-2% in patients with confirmed penicillin allergy. However, patients with a history of severe immediate hypersensitivity reactions to penicillin, particularly anaphylaxis, remain at meaningful risk and should not receive ceftriaxone without careful risk-benefit assessment and availability of emergency management resources. Patients with mild, delayed, or non-immune penicillin reactions may be able to receive ceftriaxone with appropriate precautions and monitoring.
Renal and Hepatic Impairment: Ceftriaxone is eliminated by both biliary and renal routes, which provides a degree of compensation in patients with impairment of either organ system alone. In patients with combined severe renal and hepatic impairment, accumulation of ceftriaxone can occur and dose adjustment or extended dosing intervals may be required. Regular monitoring of renal and hepatic function is advisable in patients with significant organ impairment receiving ceftriaxone.
Pregnancy and Breastfeeding: Ceftriaxone crosses the placenta and is present in fetal circulation. Animal studies have not demonstrated teratogenicity, and limited human data suggest ceftriaxone is relatively safe during pregnancy when the clinical indication is compelling. Ceftriaxone is excreted in breast milk in small amounts. The risk-benefit balance should be discussed with the patient, taking into account the severity of the infection, the availability of alternative therapies, and the stage of pregnancy or lactation.
Vitamin K and Coagulation: Ceftriaxone and other cephalosporins can suppress intestinal bacteria that produce vitamin K2, potentially leading to reduced prothrombin activity and increased bleeding tendency, particularly in malnourished patients, those receiving prolonged therapy, or those with poor dietary vitamin K intake. Prothrombin time should be monitored in at-risk patients and vitamin K supplementation considered where clinically indicated.
Storage and Handling Instructions
Store unreconstituted vials at room temperature below 25°C, protected from light and moisture. Keep in original packaging until immediately before preparation. Reconstituted solutions should be used promptly according to stability data provided in the product information. Stability varies depending on the diluent used and storage conditions. Do not use vials that show signs of damage, compromised seal integrity, discoloration, or visible contamination. Dispose of unused portions of reconstituted solution and all sharps and clinical waste in accordance with institutional infection control and hazardous waste disposal protocols. Keep out of reach of children.
Manufacturer Information
[Manufacturer name and details would be inserted here based on your specific product]
Regulatory Status: Oxidil IM Injection 250mg is a prescription-only medication for administration by or under the supervision of trained healthcare professionals. Self-administration outside of a supervised clinical setting is not appropriate.
Medical Review Notice: This product information should be reviewed by a licensed physician or clinical pharmacist with expertise in infectious disease and antimicrobial therapy to ensure accuracy and compliance with current clinical guidelines, local antimicrobial resistance patterns, and antibiotic stewardship principles. Prescribing decisions should be guided by current evidence-based guidelines for the management of specific bacterial infections and informed by local microbiological surveillance data.
Last Updated: [Date would be inserted here]